The specialized consulting firm Rare. has announced the official opening of its Healthcare Insights library to the public, offering a comprehensive repository of market data, clinical audits, and strategic analysis at no cost to industry stakeholders. This move represents a significant shift in the medical aesthetics information landscape, where high-level market intelligence has traditionally been gated behind significant paywalls or reserved for private consultancy clients. By providing free access to its proprietary platform, Rare. aims to democratize data-driven decision-making for practitioners, brand managers, and investors operating within the rapidly evolving UK aesthetics market. The platform is structured into three distinct modules—Market Insights, Market Stats, and Brand Amplification—each designed to address specific informational gaps in the sector, ranging from high-level corporate acquisition strategies to granular clinic-level treatment trends.
A Structural Overview of the Healthcare Insights Platform
The Rare. Healthcare Insights library is built upon a foundation of extensive data collection and longitudinal studies. The first pillar, Market Insights, serves as a hub for qualitative and quantitative analysis of major industry shifts. This section focuses on interpreting the "why" behind market movements, such as mergers and acquisitions or shifts in patient demographics. By synthesizing complex data into digestible reports, the platform provides a strategic lens through which professionals can view the broader economic health of the aesthetics industry.
The second pillar, Market Stats, functions as the empirical core of the library. It draws directly from Rare.’s exhaustive specialty audits, which monitor the activities and service offerings of thousands of clinics across the United Kingdom. This section is particularly valuable for benchmarking, as it allows individual clinic owners to compare their service menus against national averages and regional trends. The data presented here is updated periodically to reflect the shifting popularity of various modalities, providing a real-time pulse of the clinical environment.
The third pillar, Brand Amplification, focuses on the commercial side of the industry. It tracks brand visibility, mentions, and market share among practitioners. In an industry where brand loyalty and clinical preference are major drivers of revenue, this section offers critical insights into which manufacturers are successfully capturing the attention of the medical community. For brands, this data serves as a measure of marketing efficacy; for practitioners, it provides a glimpse into the prevailing "gold standards" of the industry.
Analyzing the 2026 UK Medical Aesthetics Audit
The most recent data release within the Market Stats category is headlined by a massive audit conducted in April 2026. Rare. successfully audited 24,937 medical aesthetics clinics across the UK, representing one of the most comprehensive surveys of the sector to date. The findings underscore the continued dominance of injectable treatments, which remain the primary revenue drivers for the vast majority of non-surgical cosmetic businesses.
According to the audit, botulinum toxin treatments (commonly referred to as Botox) remain the most ubiquitous offering, with 85.5% of all audited clinics providing this service. This high penetration rate highlights the status of neurotoxins as the "entry point" for many patients and the foundational service for practitioners. Following closely behind are dermal fillers, offered by 70.9% of clinics. The data suggests that while the filler market is slightly more fragmented than the toxin market, it remains a core pillar of clinical practice.
One of the most notable findings in the 2026 audit is the rapid rise of skin boosters. These treatments, which typically involve the injection of non-cross-linked hyaluronic acid to improve skin quality rather than add volume, are now offered by 55.7% of UK clinics. This represents a significant upward trend compared to previous years, reflecting a broader shift in patient demand toward "skin quality" and "natural rejuvenation" rather than purely structural changes. The growth of skin boosters indicates a diversification of the injectable market and suggests that clinics are successfully educating patients on the benefits of preventative and regenerative aesthetics.
Strategic Implications of Corporate Acquisitions: The Obagi Case Study
Beyond raw statistics, the Market Insights section provides a deeper dive into corporate strategy, most notably in a recent report examining the acquisition of Obagi Medical by the private equity firm Bridgepoint. Obagi, a brand historically synonymous with medical-grade topical skincare, has undergone a strategic shift under its new ownership. The Rare. analysis questions the efficacy of an "injectable-led" strategy for the UK market—a move often favored by private equity looking for high-growth scalability.
Rare.’s analysis draws on specific clinic data to challenge the assumption that injectables are the most logical companion to a premium skincare line. The data suggests a much stronger cross-sell relationship between medical-grade skincare and energy-based devices (EBDs), such as lasers, radiofrequency machines, and ultrasound technology, than between skincare and injectables.
The report argues that patients who invest in high-end topical regimens are often more inclined toward the "total skin health" approach offered by EBDs. Conversely, patients seeking injectables may be looking for immediate structural results and are not always as committed to the long-term maintenance required by medical skincare. This insight has significant implications for investors and brand managers, suggesting that a more nuanced understanding of patient pathways is required to maximize the return on investment in the aesthetics space.
Brand Visibility and the Hyaluronic Acid Market
The Brand Amplification module provides a detailed look at the competitive landscape of the UK hyaluronic acid (HA) dermal filler market. As one of the most saturated segments of the aesthetics industry, understanding brand dominance is crucial for both manufacturers and new entrants.
Rare.’s analysis identified Juvéderm, manufactured by Allergan Aesthetics (an AbbVie company), as the most-mentioned brand among UK clinics. This dominance is attributed to a combination of long-standing clinical heritage, extensive practitioner training programs, and significant direct-to-consumer marketing spend. Juvéderm is followed in visibility by Restylane (Galderma) and Teosyal (Teoxane).
The report notes that while these "big three" brands continue to hold the majority of the market share, there is increasing noise from "challenger brands" that focus on specific niches, such as lip-only fillers or bio-stimulating properties. The high visibility of established brands suggests that in a market where patient safety and predictable results are paramount, practitioners tend to gravitate toward products with the most extensive clinical backing and historical data.
Chronology of Data Collection and Industry Evolution
The opening of the Healthcare Insights library is the culmination of several years of data aggregation. The timeline of Rare.’s involvement in the sector reflects the broader professionalization of the UK aesthetics industry:
- 2020–2022: Rare. began building its database during a period of intense market volatility caused by the global pandemic. This era saw a surge in "Zoom Dysmorphia," leading to a post-lockdown boom in aesthetic procedures.
- 2023–2024: The company expanded its audit capabilities, moving from regional surveys to national datasets. This period coincided with increased government scrutiny of the UK aesthetics sector, including the first steps toward a national licensing scheme.
- 2025: Rare. refined its "Brand Amplification" metrics, using advanced sentiment analysis and digital footprint tracking to measure brand health beyond simple sales figures.
- April 2026: The completion of the landmark audit of 24,937 clinics provided the necessary scale to launch the open-access platform.
- Present: The library is officially opened to the public, marking a new era of transparency.
Broader Impact and Industry Reactions
The decision to provide free access to this data has been met with positive responses from various sectors of the industry. While Rare. has not released official statements from partners, industry analysts suggest that this move will likely force other consultancies to reconsider their value propositions.
For independent practitioners, the access to Market Stats is particularly transformative. "In an industry that is often shrouded in secrecy, having access to hard numbers regarding treatment trends allows us to make better decisions about where to invest in training and equipment," says one London-based clinic owner. "Seeing that skin boosters are now in over 50% of clinics, for instance, confirms that this isn’t just a fad—it’s a necessary part of a modern service menu."
From a regulatory perspective, the transparency provided by Rare. could assist bodies like the Joint Council for Cosmetic Practitioners (JCCP) and the Department of Health and Social Care (DHSC) in understanding the true scale and composition of the market. As the UK moves toward a mandatory licensing scheme for non-surgical cosmetic procedures, having an accurate census of clinics and the services they offer is vital for effective policy-making.
The Future of Data-Driven Aesthetics
The launch of the Healthcare Insights library signals a shift toward a more mature, data-driven aesthetics industry. Historically, the sector has relied heavily on anecdotal evidence and manufacturer-led marketing. By providing an independent, data-first perspective, Rare. is encouraging a more critical and analytical approach to business growth.
The implications for the future are clear: as the market becomes more crowded and consumer expectations rise, the "gut feeling" approach to clinic management will no longer suffice. Whether it is deciding whether to pivot toward energy-based devices or choosing which dermal filler brand to stock, the answers will increasingly be found in the data.
Rare.’s initiative suggests that the value of a consulting firm is no longer just in the possession of data, but in the ability to interpret it. By giving away the data for free, the company is positioning itself as the primary authority on its meaning, likely attracting clients who seek bespoke, high-level strategic guidance that goes beyond what is available in the public library. For now, the UK aesthetics industry has been given a powerful new tool to navigate an increasingly complex landscape, fostering a culture of transparency that benefits practitioners and patients alike.
